-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Recently, Tofflon, a leading pharmaceutical equipment company, issued a prospectus for the issuance of A shares to specific objects in 2022, which has attracted great attention in the industry
.
Pharmaceutical Equipment (Photo source: Pharmaceutical Network) The announcement shows that the total amount of funds raised from the issuance of stocks to specific objects does not exceed 3.
2 billion yuan (including this amount), and after deducting the issuance costs, it is planned to be used to invest in the biopharmaceutical equipment industry trial production center project, Jiangsu Biomedical equipment industrialization base project, Zhejiang Tofflon Biotechnology Co.
, Ltd.
life science industrialization base project and supplementary working capital
.
Among them, the total investment of the biopharmaceutical equipment industry trial production center project is 760 million yuan.
After the project is completed, the planned production capacity of the complex preparation liquid dispensing system is 157 sets of liquid dispensing systems, an increase of 68.
82% compared with the company's 93 sets of liquid dispensing systems in 2021.
.
The total investment of the Jiangsu biomedical equipment industrialization base project is 1.
09 billion yuan.
The project involves freeze-drying system, back-end light inspection and packaging line capacity expansion.
The planned production capacity is a 149.
56% increase compared to the company's 2021 output
.
The total investment of the life science industrialization base project of Zhejiang Tofflon Biotechnology Co.
, Ltd.
is 1.
3 billion yuan.
The planned production capacity is an increase of 407.
52% compared to the company's production
.
In the secondary market, Tofflon's share price has also been boosted.
The day after the company released the news (August 3), the share price of the stock rose.
As of the close of the day, the share price increased by 2.
87% to 53.
77 yuan.
The share price hit a record high of 55.
25 yuan during the session
.
It is worth mentioning that this is not Tofflon's second major expansion of production
.
As early as May 2020, Tofflon issued an announcement saying that the company plans to invest 500 million yuan to build a biopharmaceutical system equipment industrialization project, of which the first phase will invest 350 million yuan.
production, the annual output value is more than 500 million yuan
.
The purpose is to expand the production capacity of biological equipment and further enhance the company's overall solution capabilities for bioengineering
.
In addition to Tofflon, Chutian Technology is also gradually expanding its production capacity according to actual development needs.
After the first three phases of capacity expansion, the company has now built an industrial park with highly concentrated production and R&D.
After the completion of the fourth phase, it will form a global industrial park.
The scale of tens of billions of production capacity covers the bioengineering sector, intelligent after-package workshops, and intelligent traditional Chinese medicine workshops
.
In the recent survey, Chutian Technology also mentioned in detail that in the field of disposable consumables, it plans to add 200 million orders this year, and plans to add 1 billion in the future; in the field of fillers, there will be sales of small batches of products this year, using 3-5 years.
A production capacity of 500,000 liters will be built, and the future sales plan will exceed 1 billion
.
The company has planned the Chutian Science and Technology Tiger Pond Polymer Material Industrial Park in Ningxiang, and will start construction in the near future
.
Canaan Technology has also previously announced that in order to meet the growing demand for orders from the company's biologics water equipment and pharmaceutical dispensing system engineering business and smart logistics business segments, and to break through the bottleneck of production capacity, the company's holding subsidiaries Shanghai Kaixian and Canaan Feiqi It plans to set up wholly-owned subsidiaries Nanjing Kaixian and Nanjing Qiyun respectively in Gaochun District, Nanjing City
.
So, what signal has been released to the industry behind these leading pharmaceutical machine companies investing heavily in new production capacity? Tofflon's main business is divided into three major sectors: pharmaceutical equipment sector, medical technology and technology sector, and food equipment engineering sector.
In the field of biopharmaceuticals, the company can not only provide process equipment for biopharmaceutical customers, but also provide them with overall solutions.
Solutions (process + equipment + engineering), bioprocess integration and other services
.
In recent years, with the improvement of the consumption level of Chinese residents, the enhancement of health awareness, and the support of favorable policies, pharmaceutical companies have invested a lot in research and development, the domestic biopharmaceutical industry has developed rapidly, the market scale has continued to expand, and the demand for enterprise capacity expansion has accelerated.
It has brought great opportunities to the upstream biomedical equipment industry
.
According to industry forecasts, by 2030, the scale of China's biological drug market will reach 1,319.
8 billion yuan, and there is huge room for market growth
.
The market believes that the high-end pharmaceutical equipment market is ushering in a new round of opportunities, and powerful leading pharmaceutical machine companies are expected to embrace the opportunity and speed up import substitution
.
Industrial Securities once predicted that China's pharmaceutical equipment market will reach US$4.
58 billion by 2025, with a compound growth rate of 8.
1%
.
Behind the expansion of the leading pharmaceutical machine companies, it can be seen that they are determined to deploy in the field of biomedicine
.
However, Tofflon also warned of some risks, such as the inability to fully digest new production capacity, the unsatisfactory benefits of investment projects with raised funds, the decline in performance due to depreciation and amortization of new assets, decline in gross profit margin, and dependence on downstream industries, etc.
risk
.
It is foreseeable that with the expansion of production by leading companies, the competition among the leading companies will be more intense in the future in the field of biomedicine
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Pharmaceutical Equipment (Photo source: Pharmaceutical Network) The announcement shows that the total amount of funds raised from the issuance of stocks to specific objects does not exceed 3.
2 billion yuan (including this amount), and after deducting the issuance costs, it is planned to be used to invest in the biopharmaceutical equipment industry trial production center project, Jiangsu Biomedical equipment industrialization base project, Zhejiang Tofflon Biotechnology Co.
, Ltd.
life science industrialization base project and supplementary working capital
.
Among them, the total investment of the biopharmaceutical equipment industry trial production center project is 760 million yuan.
After the project is completed, the planned production capacity of the complex preparation liquid dispensing system is 157 sets of liquid dispensing systems, an increase of 68.
82% compared with the company's 93 sets of liquid dispensing systems in 2021.
.
The total investment of the Jiangsu biomedical equipment industrialization base project is 1.
09 billion yuan.
The project involves freeze-drying system, back-end light inspection and packaging line capacity expansion.
The planned production capacity is a 149.
56% increase compared to the company's 2021 output
.
The total investment of the life science industrialization base project of Zhejiang Tofflon Biotechnology Co.
, Ltd.
is 1.
3 billion yuan.
The planned production capacity is an increase of 407.
52% compared to the company's production
.
In the secondary market, Tofflon's share price has also been boosted.
The day after the company released the news (August 3), the share price of the stock rose.
As of the close of the day, the share price increased by 2.
87% to 53.
77 yuan.
The share price hit a record high of 55.
25 yuan during the session
.
It is worth mentioning that this is not Tofflon's second major expansion of production
.
As early as May 2020, Tofflon issued an announcement saying that the company plans to invest 500 million yuan to build a biopharmaceutical system equipment industrialization project, of which the first phase will invest 350 million yuan.
production, the annual output value is more than 500 million yuan
.
The purpose is to expand the production capacity of biological equipment and further enhance the company's overall solution capabilities for bioengineering
.
In addition to Tofflon, Chutian Technology is also gradually expanding its production capacity according to actual development needs.
After the first three phases of capacity expansion, the company has now built an industrial park with highly concentrated production and R&D.
After the completion of the fourth phase, it will form a global industrial park.
The scale of tens of billions of production capacity covers the bioengineering sector, intelligent after-package workshops, and intelligent traditional Chinese medicine workshops
.
In the recent survey, Chutian Technology also mentioned in detail that in the field of disposable consumables, it plans to add 200 million orders this year, and plans to add 1 billion in the future; in the field of fillers, there will be sales of small batches of products this year, using 3-5 years.
A production capacity of 500,000 liters will be built, and the future sales plan will exceed 1 billion
.
The company has planned the Chutian Science and Technology Tiger Pond Polymer Material Industrial Park in Ningxiang, and will start construction in the near future
.
Canaan Technology has also previously announced that in order to meet the growing demand for orders from the company's biologics water equipment and pharmaceutical dispensing system engineering business and smart logistics business segments, and to break through the bottleneck of production capacity, the company's holding subsidiaries Shanghai Kaixian and Canaan Feiqi It plans to set up wholly-owned subsidiaries Nanjing Kaixian and Nanjing Qiyun respectively in Gaochun District, Nanjing City
.
So, what signal has been released to the industry behind these leading pharmaceutical machine companies investing heavily in new production capacity? Tofflon's main business is divided into three major sectors: pharmaceutical equipment sector, medical technology and technology sector, and food equipment engineering sector.
In the field of biopharmaceuticals, the company can not only provide process equipment for biopharmaceutical customers, but also provide them with overall solutions.
Solutions (process + equipment + engineering), bioprocess integration and other services
.
In recent years, with the improvement of the consumption level of Chinese residents, the enhancement of health awareness, and the support of favorable policies, pharmaceutical companies have invested a lot in research and development, the domestic biopharmaceutical industry has developed rapidly, the market scale has continued to expand, and the demand for enterprise capacity expansion has accelerated.
It has brought great opportunities to the upstream biomedical equipment industry
.
According to industry forecasts, by 2030, the scale of China's biological drug market will reach 1,319.
8 billion yuan, and there is huge room for market growth
.
The market believes that the high-end pharmaceutical equipment market is ushering in a new round of opportunities, and powerful leading pharmaceutical machine companies are expected to embrace the opportunity and speed up import substitution
.
Industrial Securities once predicted that China's pharmaceutical equipment market will reach US$4.
58 billion by 2025, with a compound growth rate of 8.
1%
.
Behind the expansion of the leading pharmaceutical machine companies, it can be seen that they are determined to deploy in the field of biomedicine
.
However, Tofflon also warned of some risks, such as the inability to fully digest new production capacity, the unsatisfactory benefits of investment projects with raised funds, the decline in performance due to depreciation and amortization of new assets, decline in gross profit margin, and dependence on downstream industries, etc.
risk
.
It is foreseeable that with the expansion of production by leading companies, the competition among the leading companies will be more intense in the future in the field of biomedicine
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
